7 medtech stories we missed this week: Nov. 3, 2017

medtech missed

[Image from unsplash.com]

From Hologic’s new product launch to CapsoVision gettting CE Mark approval, here are seven medtech stories we missed this week but thought were still worth mentioning.

1. Hologic launches new MyoSure device

Hologic announced in a Nov. 1 press release that it has launched its MyoSure Manual Device in the U.S. The device is designed to help doctors resect and remove intrauterine tissue easily in an office setting if used with the MyoSure hysteroscope.

2. IntraFuse wins FDA clearance for FlexThread fibula pin

IntraFuse has received FDA 510(k) clearance for its FlexThread Fibula Pin System, according to a Nov. 1 press release. The system is designed to help improve outcomes for orthopedic extremity procedures. It has a percutaneous fixation of distal fibula fractures like Danis-Weber B type fractures or trans-syndesmotic fractures.

3. Skyline Medical, Helomics ink personalized cancer care deal

Skyline Medical and Helomics have announced their collaboration in a Nov. 1 press release to develop new approaches for personalized cancer diagnosis and care using the Helomics D-CHIP. D-CHIP uses an artificial intelligence-powered bioinformatics engine to show insights from cancer patient data to help with disease diagnosis and develop new diagnostics and therapies.

4. Sensus Healthcare wins Mexico nod

Sensus Healthcare has been cleared to sell its SRT-100 in Mexico, according to an Oct. 31 press release. The system has been approved to treat non-melanoma skin cancer and keloids and is set to be placed on the National Registry by February 2018.

5. Vesalio wins CE Mark for NeVa thrombectomy device

Vesalio announced in an Oct. 31 press release that it has received CE Mark certification for its NeVa neurotheomectomy platform for treating strokes. The mechanical thrombectomy technology was designed to improve first pass success and capture and remove clots that can create sudden blockages in blood flow to the brain.

6. BRH Medical wins FDA nod

BRH Medical has received FDA 510(k) clearance for its BRH-A2 device that reduces pain and promotes healing of deep wounds, according to an Oct. 31 press release. The technology engages and stimulates the wounded area from below the wound bed using ultrasound and electric field modalities to affect the tissues and muscles in the region of and below the wound. It can be used with any treatment modally and is portable enough to be used in clinics and hospitals.

7. Capsovision gets CE Mark

Capsovision announced in an Oct. 25 press release that it has received CE Mark approval for its CapsoCam Plus System for patients who are age 2 and older. It is a wire-free capsule endoscopy system that gives physicians a full 360º panoramic lateral image of the small bowel mucosa.

Here’s what we missed last week.

Hologic closes $1.7B Cynosure buy

Hologic, Cynosure

Hologic (NSDQ:HOLX) said today that it closed its $1.65 billion acquisition of Cynosure Inc. (NSDQ:CYNO) and its portfolio of medical aesthetic products and devices.

Marlborough, Mass.-based Hologic paid $66 per share for a total of 17 million shares of Class A stock, representing approximately 70.6% of the company’s outstanding shares.

“We are pleased to complete our acquisition of Cynosure, and look forward to working with Michael Davin and the entire Cynosure team to achieve even greater success in the large, rapidly growing medical aesthetics market. Acquiring Cynosure, combined with divesting our blood screening business, fundamentally reshapes our business portfolio and makes us a stronger, faster-growing company,” Hologic chair, prez & CEO Steve MacMillan said in a press release.

Hologic said that upon closure, Cynosure has become a wholly owned subsidiary of the company, with a discussion of financial implications of the purchase slated for May 10, along with the release of its 2nd quarter earnings.

Morgan Stanley acted as financial advisor to Hologic, while Wachtell, Lipton, Rosen & Katz served as legal advisor. Leerink Partners acted as financial advisor to Cynosure, with Wilmer Culter Pickerin Hale and Dorr as legal advisor.

Last month, Cynosure faced a class action lawsuit from shareholders who looked to halt the company’s proposed $1.44 billion sale to Hologic, alleging that Cynosure’s regulatory filing recommending the transaction is missing crucial information about the company’s financial projections and the process that led up to the deal.

The complaint, filed in the U.S. District Court for Massachusetts, suggested that the filing is misleading and that shareholders don’t have enough information to ensure the proposed transaction is a good deal.